Adverum Biotechnologies, Inc.
ADVM
$3.89
-$0.05-1.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | -- | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | -- | -- | 0.00 | -- |
| Cost of Revenue | 20.44M | 17.10M | 15.41M | 15.28M | 20.74M |
| Gross Profit | -19.44M | -17.10M | -15.41M | -15.28M | -20.74M |
| SG&A Expenses | 9.78M | 3.79M | 11.43M | 10.66M | 13.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.22M | 20.88M | 26.84M | 25.93M | 34.53M |
| Operating Income | -29.22M | -20.88M | -26.84M | -25.93M | -34.53M |
| Income Before Tax | -27.13M | -18.48M | -24.79M | -24.85M | -32.87M |
| Income Tax Expenses | -- | -- | -- | -1.13M | 17.00K |
| Earnings from Continuing Operations | -27.13M | -18.48M | -24.79M | -23.71M | -32.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.13M | -18.48M | -24.79M | -23.71M | -32.89M |
| EBIT | -29.22M | -20.88M | -26.84M | -25.93M | -34.53M |
| EBITDA | -28.33M | -19.93M | -25.84M | -24.93M | -33.02M |
| EPS Basic | -1.30 | -0.89 | -1.50 | -2.34 | -3.26 |
| Normalized Basic EPS | -0.81 | -0.55 | -0.94 | -1.52 | -2.03 |
| EPS Diluted | -1.30 | -0.89 | -1.50 | -2.34 | -3.26 |
| Normalized Diluted EPS | -0.81 | -0.55 | -0.94 | -1.52 | -2.03 |
| Average Basic Shares Outstanding | 20.88M | 20.85M | 16.48M | 10.12M | 10.10M |
| Average Diluted Shares Outstanding | 20.88M | 20.85M | 16.48M | 10.12M | 10.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
